



WORKING GROUP 3&5:

PUBLIC-PRIVATE PARTNERSHIP

Susan Tansey ad. 02/2019 / Pirkko Lepola
Chair / Co-Chair WG 3&5

Enpr-EMA WG 3&5

Role:

- Facilitate communication **between industry and networks**
- Gather examples of good practice from Networks and industry working with Enpr-EMA networks
- Develop proposals to disseminate examples of good practice to Enpr-EMA networks and industry

Enpr-EMA WG 3&5

WG 3&5 Steering Committee members:

Martine Dehlinger-Kremer

Susan Tansey (Acting Chair) –ad. 02/2019

Pirkko Lepola (Co-Chair) -> Chair – since 02/2019

Jenny Preston

Colin Hayward

Mark Sorrentino

Heidrun Hildebrand

Andrea Wassmuth

(Mark Turner)

Other members WG 3&5:

Pamela Dicks

Stefanie Breitenstein

Cristina Serén Trasorras

Task 1: Survey

Task 1.; Network & Industry survey; 12/2013 - 02/2014

Deliverable 1: Publication: ‘Pharmaceutical Industry and Pediatric Clinical Trials networks in Europe- how do they communicate?’ , Applied Clinical Trials, Jan 08 2016.
Pirkko Lepola, Susan Tansey, Pamela Dicks, Jennifer Preston, Martine Dehlinger-Kremer

Deliverable 1: Publication

- THE TRUSTED CLINICAL TRIALS BUSINESS RESOURCE -

APPLIED CLINICAL TRIALS

[Home](#) > [Pharmaceutical Industry and Pediatric Clinical Trial Networks in Europe – How Do They Communicate?](#)

Pharmaceutical Industry and Pediatric Clinical Trial Networks in Europe – How Do They Communicate?

Jan 08, 2016
By [Pirkko Lepola](#) [1], [Susan Tansey](#) [2], [Pamela Dicks](#) [3], [Jennifer Preston](#) [4], [Martine Dehlinger-Kremer](#) [5]
Applied Clinical Trials




PEER
REVIEW

Task 2: Network Consultation

- Task 2.: Network consultation recommendation; 12/2015 -> 04/2017, Distributed for consultations; 06/2016 – 08/2016, Final draft 04/2017
- Deliverable 2: Consultation recommendation document; placed on Enpr-EMA website for the sponsors and CROs;

- 05 December 2018

Version 10.0 – Consultation diagram



Deliverable 2: Recommendation



European network of paediatric research
at the European Medicines Agency




EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

5 December 2018

Enpr-EMA Working group on public-private partnership: Network consultation recommendation

Members of Enpr-EMA offer opportunities for advice and information during all stages of paediatric medicines development. Enpr-EMA suggests that all companies consider using these opportunities in a spirit of shared learning about the best way to collaborate during PIP planning and. This offer is to assist companies in taking advantage of the scientific and logistical expertise in paediatric clinical research, available from the paediatric clinical research networks of the [Enpr-EMA \(European network of paediatric research at the European Medicines Agency\)](#).

Basic idea of the Consultation Recommendation



Task 3: Pilot test – current status in 2019

- 02-03/2019 several companies (EU and US based) contacted Enpr-EMA for the pilot test
- Reaction: “conflicting” similar activities was planned to be done by C4C project – details were not known by the beginning of the year 2018 !
 - *Discussion with Enpr-EMA secretariat and the companies how to proceed*
 - *Some companies already consortium partners in IMI2 c4c project WP4 (scientific advice)*
 - *Internal decision taken on 24.5.2019;*
 - *Must align with c4c and other initiatives and avoid overlapping activities (if planned in advance);*
-> further discussion & TC for detailed clarifications

Public&Private WG status

14.10.2019

- Completed tasks (also pilot period)
- If new P&P WG is needed (?) the existing data, documentation and experience can be utilized in future tasks
- **Future:** Further ideas & actions open for dicussion accross Enpr-EMA members and working groups

